INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 23 2025
0mins
Source: Globenewswire
Phase 2 MINDFuL Trial Results: INmune Bio Inc. will present additional analyses from its Phase 2 MINDFuL trial of XPro™, a selective TNF inhibitor, at the Alzheimer’s Association International Conference, highlighting its potential to slow cognitive decline in early-stage Alzheimer's disease despite not meeting primary endpoints in the overall group.
Future Developments and Partnerships: The company plans to publish the study results by mid-August and is seeking strategic partnerships to further develop XPro™ as a treatment for Alzheimer’s disease, emphasizing the importance of targeting neuroinflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
